292 related articles for article (PubMed ID: 30350271)
1. Refractory In-Stent Restenosis: Improving Outcomes by Standardizing Our Approach.
Waksman R; Iantorno M
Curr Cardiol Rep; 2018 Oct; 20(12):140. PubMed ID: 30350271
[TBL] [Abstract][Full Text] [Related]
2. Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review.
Shlofmitz E; Iantorno M; Waksman R
Circ Cardiovasc Interv; 2019 Aug; 12(8):e007023. PubMed ID: 31345066
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
[TBL] [Abstract][Full Text] [Related]
4. Treatment of coronary artery in-stent restenosis.
Kokkinidis DG; Waldo SW; Armstrong EJ
Expert Rev Cardiovasc Ther; 2017 Mar; 15(3):191-202. PubMed ID: 28116914
[TBL] [Abstract][Full Text] [Related]
5. Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) study.
Adriaenssens T; Dens J; Ughi G; Coosemans M; Onsea K; Dubois C; Sinnaeve P; Vrolix M; Desmet W
EuroIntervention; 2011 May; 7 Suppl K():K100-5. PubMed ID: 22027717
[TBL] [Abstract][Full Text] [Related]
6. Second-generation drug-eluting stents versus drug-coated balloons for the treatment of coronary in-stent restenosis: A systematic review and meta-analysis.
Kokkinidis DG; Prouse AF; Avner SJ; Lee JM; Waldo SW; Armstrong EJ
Catheter Cardiovasc Interv; 2018 Aug; 92(2):285-299. PubMed ID: 29024274
[TBL] [Abstract][Full Text] [Related]
7. Biological effect on drug distribution and vascular healing via paclitaxel-coated balloon technology in drug eluting stent restenosis swine model.
Li Y; Tellez A; Rousselle SD; Dillon KN; Garza JA; Barry C; Granada JF
Catheter Cardiovasc Interv; 2016 Jul; 88(1):89-98. PubMed ID: 26613810
[TBL] [Abstract][Full Text] [Related]
8. Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.
Rittger H; Wöhrle J; Brachmann J; Hohenforst-Schmidt W; Schlundt C; Lonke S; von Cranach M; Markovic S; Achenbach S; Waliszewski M
Catheter Cardiovasc Interv; 2016 Oct; 88(4):529-534. PubMed ID: 26893095
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
10. Evaluation and management of drug-eluting stent in-stent restenosis.
Parfrey S; Siu V; Graham JJ; Vijayaraghavan R; Li C; Pang J; Kalra S; Džavík V; Wijeysundera HC; Bagai A;
Curr Opin Cardiol; 2023 Sep; 38(5):433-440. PubMed ID: 37477129
[TBL] [Abstract][Full Text] [Related]
11. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of drug-eluting balloon in patients with bare-metal or drug-eluting stent restenosis.
Berta B; Jambrik Z; Kohar K; Szabo G; Ruzsa Z; Molnar L; Barczi G; Geller L; Becker D; Merkely B
Hellenic J Cardiol; 2014; 55(5):369-77. PubMed ID: 25243435
[TBL] [Abstract][Full Text] [Related]
13. Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation.
Kang IS; Shehata I; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
Heart Vessels; 2016 Sep; 31(9):1405-11. PubMed ID: 26337620
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial.
Baan J; Claessen BE; Dijk KB; Vendrik J; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; de Winter RJ; Koch KT; Sjauw KD; Beijk MA; Vis MM; Wykrzykowska JJ; Piek JJ; Tijssen JGP; Henriques JPS
JACC Cardiovasc Interv; 2018 Feb; 11(3):275-283. PubMed ID: 29413242
[TBL] [Abstract][Full Text] [Related]
16. Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation.
Tada T; Kadota K; Hosogi S; Miyake K; Ohya M; Amano H; Izawa Y; Kanazawa T; Kubo S; Ichinohe T; Hyoudou Y; Hayakawa Y; Sabbah MM; Otsuru S; Hasegawa D; Habara S; Tanaka H; Fuku Y; Katoh H; Goto T; Mitsudo K
Eur Heart J Cardiovasc Imaging; 2015 Oct; 16(10):1101-11. PubMed ID: 25762559
[TBL] [Abstract][Full Text] [Related]
17. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry.
Lee JM; Rhee TM; Hahn JY; Hwang D; Park J; Park KW; Kim HL; Kim SH; Chae IH; Doh JH; Jeon KH; Choi YJ; Park JS; Choi SH; Gwon HC; Koo BK; Alfonso F; Kim HS
Int J Cardiol; 2017 Mar; 230():181-190. PubMed ID: 28043660
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study.
Unverdorben M; Vallbracht C; Cremers B; Heuer H; Hengstenberg C; Maikowski C; Werner GS; Antoni D; Kleber FX; Bocksch W; Leschke M; Ackermann H; Boxberger M; Speck U; Degenhardt R; Scheller B
EuroIntervention; 2015 Dec; 11(8):926-34. PubMed ID: 25169589
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
20. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
